Women were less than half of the people tested for almost all of these common medicines.

Trouble sleeping

zolpidem

In 2013 the FDA cut the dose for women in half after finding next-morning drowsiness โ€” yet none of these studies looked at women's results separately.

  • 64.6%

    of the people in the studies were women

  • 49%

    of studies did not allow pregnant women

  • 0%

    looked at results for women separately

Was someone like me tested?

Choose the group that fits you.

Not one of these studies reported results separately for any of the groups below.

Not studied

Pregnant women

49% of studies would not let pregnant women join, and we found no study that tested this medicine in pregnancy.

What do we know?

What the FDA drug label says

Taking it late in pregnancy can make newborns very sleepy and slow their breathing. It wasn't studied in pregnant women.

Good to know

Women clear zolpidem from the body more slowly than men. In 2013 the FDA cut the recommended starting dose for women in half (to 5 mg) after reports of drowsy driving the next morning.

What women report more

Compared with men taking the same medicine.

  • 3.0ร—Physical symptoms with no clear cause
  • 1.9ร—Hives and swelling of the face, lips or throat
  • 1.9ร—Changes to the front of the eye
  • 1.6ร—Autoimmune problems (the body attacking itself)

How many times more often women reported each problem than men taking the same medicine, based on reports to the FDA. This is a warning sign, not proof the medicine caused it.

Make it about you

Check it against your medicines

Check zolpidem against the medicines, pregnancy and birth control in your profile.

Join to check

Women's experiences

Join or sign in to share, like or save. You'll fill in a short health profile so your story has context and we can check your medicines.

No one has shared yet. Your story could help the next woman.

All the details

Every number behind this page.

Who was in the studies

5,061 people in 37 studies

3,267 womenmiddle line = equal numbers1,794 men

Race

  • White75.3%
  • Black / African American19.2%
  • Asian2.2%
  • Hispanic / Latina1.1%
  • Other0.6%

Studies didn't say how many of the women were Black, Asian or another race โ€” only totals for everyone.

Hispanic or Latina
13.3%
Age 65 or older
5.1%
Studies with men only
1
Studies with women only
1
Rules that kept women out

Share of studies with each rule.

  • 77%

    No mental health conditions

    Women with depression, bipolar disorder or other mental health conditions were turned away.

    See the exact rule
    โ€œBeck Depression Inventory - II (BDI-II) score \>19 at Screeningโ€ NCT02783729
  • 51%

    Age limit under 65

    Older women were turned away, even though they often take this medicine.

    See the exact rule
    โ€œMaximum age: 64 Years.โ€ NCT00608985
  • 49%

    No pregnant women

    Women who were pregnant could not join.

    See the exact rule
    โ€œPlans to father a child while enrolled in this study or within 3 months after the last dose of study drug; and/or, Is pregnant, or breastfeeding, while enrolled in this study or within 1 month after the last dose of study drugโ€ NCT03375203
  • 36%

    No breastfeeding moms

    Women who were breastfeeding could not join.

    See the exact rule
    โ€œPlans to father a child while enrolled in this study or within 3 months after the last dose of study drug; and/or, Is pregnant, or breastfeeding, while enrolled in this study or within 1 month after the last dose of study drugโ€ NCT03375203
  • 33%

    Weight limit (BMI)

    Women with a higher (or lower) body weight were turned away.

    See the exact rule
    โ€œBody Mass Index \> 33โ€ NCT00784875
  • 31%

    No smokers

    Women who smoke or use nicotine were turned away.

    See the exact rule
    โ€œImportant caffeine consumption, heavy tobacco use, alcohol or drug abuse within 2 years prior to the screening visit.โ€ NCT00608985
What nobody checked

Share of studies that recorded each thing.

  • 0%
    Results shown separately for women
  • 0%
    Whether anyone was pregnant
  • 0%
    Whether women were past menopause
  • 15%
    Body weight (BMI)
  • 39%
    Hispanic / Latina or not
  • 72%
    Race
All 39 studies

Study titles and rules are shown in their original English.

StudyPhasepeople% women
Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)
NCT02783729
31,00686.4%
Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia
NCT00608985
370761.7%
An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia
NCT00784875
240759%
A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder
NCT03375203
236467.6%
Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder
NCT02839200
235964.1%
A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia
NCT00466193
329568.1%
Sequenced Therapies for Comorbid and Primary Insomnias
NCT01651442
โ€”21162.6%
CBT-I or Zolpidem/Trazodone for Insomnia
NCT04468776
415576.6%
Facilitation of Zolpidem (โ‰ฅ10 mg) Discontinuation Through Use of Ramelteon in Subjects With Chronic Insomnia
NCT00492232
413567.4%
The Role of Sleep in the Treatment of Cannabis Use Disorders
NCT01685073
2/312737.8%
A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006
NCT01463098
112248.4%
Partial Reinforcement II: Three Approaches to Maintenance Therapy for Chronic Insomnia
NCT03774810
411575.7%
Reducing Suicidal Ideation Through Insomnia Treatment
NCT01689909
410362.1%
A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia
NCT00380081
38270.7%
A Comparison of Midazolam and Zolpidem as Oral Premedication in Children
NCT02096900
38050%
A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)
NCT00770510
2/37240.3%
Two Contrasting Interventions for Sleep Management
NCT01804036
2/371โ€”
Characteristics of Sleep Patterns in Young Adults With and Without Insomnia
NCT00177216
46955.1%
Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients
NCT00086281
46023.3%
Lavender vs Zolpidem Sleep Quality During Diagnostic PSG
NCT04102345
Early 15745.6%
The Role of Partial Reinforcement in the Long Term Management of Insomnia
NCT00662155
โ€”5578.2%
Assess the Effect of Zolpidem, Silenor & Placebo on Arousability, Ataxia/Balance & Cognition in Healthy Volunteers
NCT02353299
4520%
Xyrem(Sodium Oxybate) and Ambien(Zolpidem Tartrate) in the Treatment of Chronic Insomnia.
NCT00383643
24866.7%
Safety and Efficacy of Chronic Hypnotic Use 2
NCT02456532
44187.8%
Driving Performance After Middle of the Night Administration of 3.5 mg Zolpidem Tartrate Sublingual Tablet
NCT01106859
14050%
Fed Bioequivalence Study of Zolpidem Tartrate Tablets and Ambienยฎ Tablets
NCT00658541
13823.7%
Bioequivalence Study of Zolpidem Tartrate Tablets and Ambienยฎ Under Fasting Conditions
NCT00684814
13855.3%
Zolpidem Tartrate 10 mg Tablets Under Fasting Conditions
NCT00833521
13815.8%
Memory Consolidation in Pharmacologically Enhanced Naps
NCT00777829
โ€”3050%
Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Zolpidem Tartrate Tablets Under Fed Conditions
NCT00939367
13036.7%
Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Zolpidem Tartrate Tablets Under Fasted Conditions
NCT00939536
12433.3%
Zolpidem Tartrate 10 mg Tablets Under Non-Fasting Conditions
NCT00833937
12412.5%
Long Term Treatment With Zolpidem: Nightly and Intermittent Dosing
NCT00156533
42070%
Zolpidem CR and Hospitalized Patients With Dementia
NCT00814502
โ€”1741.2%
Sedative-Anxiolytic Effects on Simulated Driving Performance
NCT03297944
41560%
Sleep and Breathing in the General Population - Chemical Stimuli
NCT04720547
41118.2%
Polysomnographic Study Comparing the Use of Dexmedetomidine and Zolpidem to Induce Natural Sleep
NCT01485393
โ€”1040%
Improving Sleep Quality in Heart Failure
NCT03307005
4520%
Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women
NCT00676026
โ€”โ€”โ€”